These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 2697430)

  • 21. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide.
    Galimberti M; Polchi P; Lucarelli G; Angelucci E; Baronciani D; Giardini C; Gaziev D; Erer B; Ripalti M; Rapa S
    Bone Marrow Transplant; 1994 Feb; 13(2):197-201. PubMed ID: 8205089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of leukemia with partially matched related bone marrow transplantation.
    Munn RK; Henslee-Downey PJ; Romond EH; Marciniak EJ; Fleming DR; Messino MJ; Macdonald JS; Rayens MK; Harder EJ; Phillips GL; Thompson JS
    Bone Marrow Transplant; 1997 Mar; 19(5):421-7. PubMed ID: 9052906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
    Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B
    Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.
    Mehta J; Powles R; Treleaven J; Horton C; Tait D; Meller S; Pinkerton CR; Middleton G; Eisen T; Singhal S
    Bone Marrow Transplant; 1996 Oct; 18(4):741-6. PubMed ID: 8899189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
    Wu DP; Milpied N; Moreau P; Mechinaud-Lacroix F; Mahe B; Le Tortorec S; Rapp MJ; Bourdin S; Mahe JM; Harousseau JL
    Bone Marrow Transplant; 1994 Nov; 14(5):751-7. PubMed ID: 7889008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
    Brown JR; Kim HT; Li S; Stephans K; Fisher DC; Cutler C; Ho V; Lee SJ; Milford EL; Ritz J; Antin JH; Soiffer RJ; Gribben JG; Alyea EP
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1056-64. PubMed ID: 17084369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone marrow transplantation from donors other than HLA identical siblings. What have we learned from previous experiences?
    Hervé P; Cahn JY; Tiberghien P; Racadot E; Plouvier E; Flesch M; Wijdenes J
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():112-4. PubMed ID: 2390637
    [No Abstract]   [Full Text] [Related]  

  • 29. Graft-versus-leukemia activity after T-cell depletion using counterflow centrifugation.
    de Witte T; Preijers F; Schattenberg A
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():103-5. PubMed ID: 2202463
    [No Abstract]   [Full Text] [Related]  

  • 30. Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2).
    Copelan EA; Biggs JC; Szer J; Thompson JM; Crilley P; Brodsky I; Klein JL; Kapoor N; Harman GS; Avalos BR
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):33-8; quiz 39. PubMed ID: 8342074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia.
    Ballen KK; Gilliland DG; Guinan EC; Hsieh CC; Parsons SK; Rimm IJ; Ferrara JL; Bierer BE; Weinstein HJ; Antin JH
    Bone Marrow Transplant; 1997 Nov; 20(9):737-43. PubMed ID: 9384475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cure after allogeneic bone marrow transplantation: chemo-radiotherapy and/or graft-versus-leukemia?
    Hagenbeek A; Martens AC; Schultz FW; van Bekkum DW
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():91-3. PubMed ID: 2390645
    [No Abstract]   [Full Text] [Related]  

  • 34. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pilot study of busulfan and melphalan as preparatory regimen prior to allogeneic bone marrow transplantation in refractory or relapsed hematological malignancies.
    Vey N; De Prijck B; Faucher C; Stoppa AM; Sainty D; Lafage M; Bouabdallah R; Chabannon C; Camerlo J; Gastaut JA; Maraninchi D; Blaise D
    Bone Marrow Transplant; 1996 Sep; 18(3):495-9. PubMed ID: 8879608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic bone marrow transplantation following busulfan and 90 mg/kg of cyclophosphamide.
    Avalos BR; Klein JL; Kapoor N; Copelan EA
    Bone Marrow Transplant; 1993 Dec; 12(6):655-8. PubMed ID: 8136749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): an update.
    Brodsky I; Biggs JC; Szer J; Crilley P; Atkinson K; Downs K; Dodds A; Concannon AJ; Avalos BR; Tutschka P
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):27-31; quiz 32. PubMed ID: 8342072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
    Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
    Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Replacing total body irradiation with busulfan as conditioning of patients with leukemia for allogeneic marrow transplantation.
    Tutschka PJ; Copelan EA; Kapoor N
    Transplant Proc; 1989 Feb; 21(1 Pt 3):2952-4. PubMed ID: 2650402
    [No Abstract]   [Full Text] [Related]  

  • 40. Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue.
    Lu C; Braine HG; Kaizer H; Saral R; Tutschka PJ; Santos GW
    Cancer Treat Rep; 1984 May; 68(5):711-7. PubMed ID: 6373004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.